Neuralink's First Human Trial Results Published in Prestigious Medical Journal
Neuralink, the brain implant company founded by Elon Musk, has submitted a scientific paper to the prestigious New England Journal of Medicine. The paper details the results from the first three patients who received the Neuralink device, with the Barrow Neurological Institute confirming its role as a clinical trial site. The paper, submitted by Neuralink and the Barrow Neurological Institute, provides safety data from the first three patients who underwent the implantation procedure. Michael Lawton, CEO of the Barrow Neurological Institute, confirmed the submission and his institution's involvement in the trial. The results from these initial patients are a significant milestone for Neuralink, marking the first time the company has shared detailed data from its human trials. While the paper does not disclose the names of the patients, it offers insights into the safety and potential of the Neuralink device. Neuralink's submission to the New England Journal of Medicine is a crucial step in demonstrating the safety and efficacy of its brain implant technology. The results from the first three patients, as outlined in the paper, will contribute to the ongoing dialogue and development of neural interfaces. The Barrow Neurological Institute's involvement further solidifies the credibility of these early trials.